156 related articles for article (PubMed ID: 37638172)
1. Targeted and efficient delivery of rifampicin to macrophages involved in non-tuberculous mycobacterial infection
Chae J; Kang SH; Kim J; Choi Y; Kang SH; Choi J
Nanoscale Adv; 2023 Aug; 5(17):4536-4545. PubMed ID: 37638172
[TBL] [Abstract][Full Text] [Related]
2. Anticancer and Antibacterial Properties of Curcumin-Loaded Mannosylated Solid Lipid Nanoparticles for the Treatment of Lung Diseases.
Chae J; Choi Y; Hong J; Kim N; Kim J; Lee HY; Choi J
ACS Appl Bio Mater; 2024 Apr; 7(4):2175-2185. PubMed ID: 38478917
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of Antimycobacterial Activity of Rifampicin Using Mannose-Anchored Lipid Nanoparticles against Intramacrophage Mycobacteria.
Mistry N; Bandyopadhyaya R; Mehra S
ACS Appl Bio Mater; 2022 Dec; 5(12):5779-5789. PubMed ID: 36441965
[TBL] [Abstract][Full Text] [Related]
4. Mannosylated graphene oxide as macrophage-targeted delivery system for enhanced intracellular M.tuberculosis killing efficiency.
Pi J; Shen L; Shen H; Yang E; Wang W; Wang R; Huang D; Lee BS; Hu C; Chen C; Jin H; Cai J; Zeng G; Chen ZW
Mater Sci Eng C Mater Biol Appl; 2019 Oct; 103():109777. PubMed ID: 31349400
[TBL] [Abstract][Full Text] [Related]
5. Inhalable solid lipid nanoparticles for intracellular tuberculosis infection therapy: macrophage-targeting and pH-sensitive properties.
Ma C; Wu M; Ye W; Huang Z; Ma X; Wang W; Wang W; Huang Y; Pan X; Wu C
Drug Deliv Transl Res; 2021 Jun; 11(3):1218-1235. PubMed ID: 32946043
[TBL] [Abstract][Full Text] [Related]
6. Mannosylated solid lipid nanoparticles for the selective delivery of rifampicin to macrophages.
Vieira ACC; Chaves LL; Pinheiro M; Lima SAC; Ferreira D; Sarmento B; Reis S
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):653-663. PubMed ID: 29433346
[TBL] [Abstract][Full Text] [Related]
7. Fabrication and Characterization of Surface Engineered Rifampicin Loaded Lipid Nanoparticulate Systems for the Potential Treatment of Tuberculosis: An In Vitro and In Vivo Evaluation.
Chokshi NV; Rawal S; Solanki D; Gajjar S; Bora V; Patel BM; Patel MM
J Pharm Sci; 2021 May; 110(5):2221-2232. PubMed ID: 33610570
[TBL] [Abstract][Full Text] [Related]
8. Formulation, optimization, and characterization of rifampicin-loaded solid lipid nanoparticles for the treatment of tuberculosis.
Chokshi NV; Khatri HN; Patel MM
Drug Dev Ind Pharm; 2018 Dec; 44(12):1975-1989. PubMed ID: 30058392
[TBL] [Abstract][Full Text] [Related]
9. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug.
Jain A; Agarwal A; Majumder S; Lariya N; Khaya A; Agrawal H; Majumdar S; Agrawal GP
J Control Release; 2010 Dec; 148(3):359-67. PubMed ID: 20854859
[TBL] [Abstract][Full Text] [Related]
10. Newly synthesized surfactants for surface mannosylation of respirable SLN assemblies to target macrophages in tuberculosis therapy.
Maretti E; Costantino L; Buttini F; Rustichelli C; Leo E; Truzzi E; Iannuccelli V
Drug Deliv Transl Res; 2019 Feb; 9(1):298-310. PubMed ID: 30484257
[TBL] [Abstract][Full Text] [Related]
11. Mannosylated solid lipid nanoparticles for lung-targeted delivery of Paclitaxel.
Sahu PK; Mishra DK; Jain N; Rajoriya V; Jain AK
Drug Dev Ind Pharm; 2015 Apr; 41(4):640-9. PubMed ID: 24564799
[TBL] [Abstract][Full Text] [Related]
12. Design and statistical modeling of mannose-decorated dapsone-containing nanoparticles as a strategy of targeting intestinal M-cells.
Vieira AC; Chaves LL; Pinheiro M; Ferreira D; Sarmento B; Reis S
Int J Nanomedicine; 2016; 11():2601-17. PubMed ID: 27354792
[TBL] [Abstract][Full Text] [Related]
13. Mannose-functionalized solid lipid nanoparticles are effective in targeting alveolar macrophages.
Costa A; Sarmento B; Seabra V
Eur J Pharm Sci; 2018 Mar; 114():103-113. PubMed ID: 29229273
[TBL] [Abstract][Full Text] [Related]
14. Dual Rifampicin and Isoniazid Mannose-Decorated Lipopolysaccharide Nanospheres for Macrophage- Targeted Lung Delivery.
Sumaila M; Kumar P; Ubanako P; Adeyemi SA; Choonara YE
Curr Drug Deliv; 2023; 20(10):1487-1503. PubMed ID: 35959905
[TBL] [Abstract][Full Text] [Related]
15. Lactoferrin-appended solid lipid nanoparticles of paclitaxel for effective management of bronchogenic carcinoma.
Pandey V; Gajbhiye KR; Soni V
Drug Deliv; 2015 Feb; 22(2):199-205. PubMed ID: 24467582
[TBL] [Abstract][Full Text] [Related]
16. Surface engineering of Solid Lipid Nanoparticle assemblies by methyl α-d-mannopyranoside for the active targeting to macrophages in anti-tuberculosis inhalation therapy.
Maretti E; Costantino L; Rustichelli C; Leo E; Croce MA; Buttini F; Truzzi E; Iannuccelli V
Int J Pharm; 2017 Aug; 528(1-2):440-451. PubMed ID: 28624659
[TBL] [Abstract][Full Text] [Related]
17. In Vivo Biodistribution of Respirable Solid Lipid Nanoparticles Surface-Decorated with a Mannose-Based Surfactant: A Promising Tool for Pulmonary Tuberculosis Treatment?
Truzzi E; Nascimento TL; Iannuccelli V; Costantino L; Lima EM; Leo E; Siligardi C; Gualtieri ML; Maretti E
Nanomaterials (Basel); 2020 Mar; 10(3):. PubMed ID: 32245153
[TBL] [Abstract][Full Text] [Related]
18. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
19. Rifampicin loaded mannosylated cationic nanostructured lipid carriers for alveolar macrophage-specific delivery.
Song X; Lin Q; Guo L; Fu Y; Han J; Ke H; Sun X; Gong T; Zhang Z
Pharm Res; 2015 May; 32(5):1741-51. PubMed ID: 25407545
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD44 and EGFR Dual-Targeted Solid Lipid Nanoparticles for Delivery of Doxorubicin to Triple-Negative Breast Cancer Cell Line: Preparation, Statistical Optimization, and
Darabi F; Saidijam M; Nouri F; Mahjub R; Soleimani M
Biomed Res Int; 2022; 2022():6253978. PubMed ID: 35845934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
